Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PROCEPT BioRoboticsPRCT -0.10%70 3-Year EBITDA Growth Rate is 4.80% as of Mar. 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $93.62 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 692 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 56.21% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 2.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of PROCEPT BioRobotics was 20.20% per year. The lowest was -17.50% per year. And the median was -4.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PROCEPT BioRobotics 3-Year EBITDA Growth Rate Related Terms
PRCT vs ENOV, INSP, IRMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.80% mean?
PROCEPT BioRobotics (PRCT) has a 3-Year EBITDA Growth Rate of 4.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #389 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 56.2%.
Is PROCEPT BioRobotics' 3-Year EBITDA Growth Rate too high?
PROCEPT BioRobotics' current 3-Year EBITDA Growth Rate is 4.80%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.65. PROCEPT BioRobotics' value of 4.80% is 37.3% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #389 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' 3-Year EBITDA Growth Rate compare to ENOV and INSP?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #389 out of 692 companies for 3-Year EBITDA Growth Rate. This places PROCEPT BioRobotics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.65. PROCEPT BioRobotics' value of 4.80% is 37.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current 3-Year EBITDA Growth Rate of 4.80% is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current 3-Year EBITDA Growth Rate is 4.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $93.62, compared to a current price of $19.22 — trading 79.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.80% and 37.3% below the Medical Devices & Instruments industry median of 7.65. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current 3-Year EBITDA Growth Rate is 4.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $19.22 is trading 79.5% below its estimated GF Value™ of $93.62.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
3-Year EBITDA Growth Rate: 4.80%
GF Value™: $93.62 vs. price of $19.22 (79.5% below fair value)
Industry Position: 37.3% below the Medical Devices & Instruments median (#389 of 692)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
